XML 97 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Significant agreements - Bayer Collaboration Agreement (Details)
$ in Thousands, £ in Millions
 12 Months Ended
May 04, 2023
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
May 04, 2023
GBP (£)
item
Significant agreements.          
Revenue from collaborative arrangement   $ 35,275 $ 26,976 $ 14,463  
Deferred revenue   101,658 135,194 61,873  
Bayer Collaboration Agreement          
Significant agreements.          
Number of collaboration targets | item 2       2
Upfront cash payment $ 45,000        
Milestone payments, receivable | £         £ 583.5
Period to terminate agreement upon written notice for uncured material breach 90 days        
Number of business days to terminate agreement upon non payment by Bayer 20 days        
Estimated amount payable to CROs $ 2,500        
Transaction price $ 47,500        
Expected period for satisfaction of performance obligations 4 years        
Material rights exercise period 7 years        
Revenue from collaborative arrangement   3,393 1,160 $ 0  
Deferred revenue   $ 39,960 $ 43,618    
Bayer Collaboration Agreement | Minimum          
Significant agreements.          
Number of candidate compounds into further development | item 1       1
Threshold period to terminate agreement upon written notice by Bayer 60 days        
Bayer Collaboration Agreement | Maximum          
Significant agreements.          
Number of collaboration targets | item 3       3
Milestone payments receivable | £         £ 194.5
Threshold period to terminate agreement upon written notice by Bayer 90 days        
Bayer Collaboration Agreement | Development and regulatory milestones | Maximum          
Significant agreements.          
Milestone payments receivable | £         178.3
Bayer Collaboration Agreement | Across all three potential target programs          
Significant agreements.          
Milestone payments receivable | £         £ 534.9